

World Journal of *Clinical Cases*

World J Clin Cases 2023 December 16; 11(35): 8242-8433



EDITORIAL

- 8242 Antibiotic treatment in cirrhotic patients
Fiore M, Leone S

MINIREVIEWS

- 8247 Research progress on preparation of lateral femoral tunnel and graft fixation in anterior cruciate ligament reconstruction
Dai Y, Gao WJ, Li WC, Xiang XX, Wang WM
- 8256 Accessory navicular in children
Xiang F, Liu ZQ, Zhang XP, Li YJ, Wen J
- 8263 Non-pharmacological pain palliation methods in chronic pancreatitis
Tez M, Şahingöz E, Marth HF

ORIGINAL ARTICLE**Retrospective Study**

- 8270 Ratio of hemoglobin to mean corpuscular volume: A new index for discriminating between iron deficiency anemia and thalassemia trait
Yao QC, Zhai HL, Wang HC
- 8276 Influence of standardized nursing intervention combined with mindfulness stress reduction training on the curative effect in patients with acute pancreatitis
Li S, Yin D, Guo XC
- 8284 Clinical analysis of 114 cases of bronchiolitis in infants
Shi C, Wu MH, Zuo A, Yang MM, Jiang RR
- 8291 Endovenous laser treatment *vs* conventional surgery for great saphenous vein varicosities: A propensity score matching analysis
Li Q, Zhang C, Yuan Z, Shao ZQ, Wang J
- 8300 Efficacy of prednisone combined with mycophenolate mofetil for immunoglobulin A nephropathy with moderate-to-severe renal dysfunction
Meng MJ, Hu L, Fan Y, Gao H, Chen HZ, Chen CM, Qi Z, Liu B
- 8310 Efficacy of surgical resection and ultra-reduced tension suture combined with superficial radiation in keloid treatment
Hu XY, Yang Q, Guan XY, Li JY, Wang LL, Li K, Zhang XT

Observational Study

- 8320 Prior abdominal surgery as a potential risk factor for colonic diverticulosis or diverticulitis
Ariam E, Richter V, Bermont A, Sandler Y, Cohen DL, Shirin H

META-ANALYSIS

- 8330 Vericiguat treatment of heart failure: A systematic review and meta-analysis
Yang H, Luo C, Lan WQ, Tang YH

CASE REPORT

- 8343 Rare synchronous colorectal carcinoma with three pathological subtypes: A case report and review of the literature
Li F, Zhao B, Zhang L, Chen GQ, Zhu L, Feng XL, Yao H, Tang XF, Yang H, Liu YQ
- 8350 Twin pregnancy with sudden heart failure and pulmonary hypertension after atrial septal defect repair: A case report
Tong CX, Meng T
- 8357 Diffuse arterial atherosclerosis presenting with acute ischemic gastritis: A case report
Wei RY, Zhu JH, Li X, Wu JY, Liu JW
- 8364 Balloon venoplasty for disdialysis syndrome due to pacemaker-related superior vena cava syndrome with chylothorax post-bacteraemia: A case report
Yamamoto S, Kamezaki M, Ooka J, Mazaki T, Shimoda Y, Nishihara T, Adachi Y
- 8372 Malignant pleural mesothelioma mimics thoracic empyema: A case report
Yao YH, Kuo YS
- 8379 Multifocal papillary thyroid cancer in Graves' disease: A case report
Alzaman N
- 8385 Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report
Wu RT, Zhang JC, Fang CN, Qi XY, Qiao JF, Li P, Su L
- 8392 Ankle and toe weakness caused by calcified ligamentum flavum cyst: A case report
Jung HY, Kim GU, Joh YW, Lee JS
- 8399 Atypical case of bow hunter's syndrome linked to aberrantly coursing vertebral artery: A case report
Ahn JH, Jun HS, Kim IK, Kim CH, Lee SJ
- 8404 Phleboscrosis: An overlooked complication of varicose veins that affects clinical outcome: A case report
Ren SY, Qian SY, Gao RD
- 8411 Inflammatory cutaneous metastases originating from gastric cancer: A case report
Tian L, Ye ZB, Du YL, Li QF, He LY, Zhang HZ

8416 Metastatic pancreatic solitary fibrous tumor: A case report

Yi K, Lee J, Kim DU

8425 Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report

Yamashiro H, Morii N

LETTER TO THE EDITOR

8431 Letter to the editor: Aggressive variant prostate cancer: An exemplary case study and comprehensive literature survey

Ke HW, Zhang WY, Xu KX

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Md Moshir Rahman, MBBS, Assistant Professor, Department of Neurosurgery, Holy Family Red Crescent Medical College Hospital, Dhaka 1000, Bangladesh. dr.tutul@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJCC* as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Hua-Ge Yu*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jim-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogorgos, Maurizio Serati

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

December 16, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report

Hiroyasu Yamashiro, Nao Morii

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Beeraka NM, India

Received: October 11, 2023

Peer-review started: October 11, 2023

First decision: October 24, 2023

Revised: November 4, 2023

Accepted: November 30, 2023

Article in press: November 30, 2023

Published online: December 16, 2023



Hiroyasu Yamashiro, Nao Morii, Department of Breast Surgery, Tenri Hospital, Nara, Tenri 632-8552, Japan

Corresponding author: Hiroyasu Yamashiro, MD, PhD, Director, Department of Breast Surgery, Tenri Hospital, No. 200 Mishima-cho, Nara, Tenri 632-8552, Japan.
yamashiro.bcs@gmail.com

Abstract

BACKGROUND

This case report addresses the dearth of effective therapeutic interventions for central nervous system metastases in patients with HER2-negative breast cancer. It presents a unique case of a woman with estrogen receptor-positive, HER2-negative breast cancer who developed brain metastasis. The report highlights her initial favorable response to abemaciclib and letrozole therapy prior to the discontinuation due to drug-induced lung damage (DILD).

CASE SUMMARY

In this comprehensive case summary, we present the clinical course of a woman in her 60s, who 11 years following primary breast cancer surgery, was diagnosed with multiple brain metastases. As a third-line systemic therapy, she underwent treatment with abemaciclib and letrozole. This treatment approach yielded a near-partial response in her metastatic brain lesions. However, abemaciclib administration ceased due to the emergence of DILD, as confirmed by a computed tomography scan. The DILD improved after 1 mo of cessation. Despite ongoing therapeutic efforts, the patient's condition progressively deteriorated, ultimately resulting in death due to progression of the brain metastases.

CONCLUSION

This case underscores the challenge of managing adverse events in responsive brain metastasis patients, given the scarcity of therapeutic options.

Key Words: Breast cancer; HER2 negative; Brain metastasis; Abemaciclib; Drug-induced interstitial lung damage; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: In this case report, we address the critical issue of limited therapeutic options for HER2-negative breast cancer patients with brain metastases. We present a case of a woman with estrogen receptor-positive, HER2-negative breast cancer who initially exhibited an encouraging response to abemaciclib and letrozole therapy for brain metastases. However, this treatment had to be discontinued due to drug-induced lung damage. This study reports the challenges of achieving a balance between efficacy and adverse events in managing brain metastases and highlights the need for alternative treatment strategies in this patient population.

Citation: Yamashiro H, Morii N. Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report. *World J Clin Cases* 2023; 11(35): 8425-8430
URL: <https://www.wjgnet.com/2307-8960/full/v11/i35/8425.htm>
DOI: <https://dx.doi.org/10.12998/wjcc.v11.i35.8425>

INTRODUCTION

Central nervous system (CNS) metastasis in primary breast cancer occurs in 10%-15% of advanced/recurrent breast cancer cases[1]. However, drug therapy for brain metastases has been considered less effective due to the presence of the brain-blood barrier (BBB), which restricts the entry of many drugs into the CNS. In certain phenotypes, such as HER2-positive breast cancer, treatment outcomes of CNS metastasis have been improving with the development of new drugs [2]. However, there is currently no drug that has significant efficacy in treating CNS metastasis from HER2 negative breast cancer, and radiation therapy remains the first choice.

Cyclin-dependent kinase (CDK) 4/6 inhibitors, abemaciclib and palbociclib, are available as insurance-covered treatment in Japan. These drugs, when combined with hormonal therapy, were twice as effective in prolonging progression-free interval in estrogen receptor (ER)-positive/HER2-negative metastatic/recurrent breast cancer compared to hormonal therapy alone[3]. Abemaciclib can cross the BBB[4], and it is expected to be effective against brain metastasis of ER-positive/HER2-negative breast cancer.

Here, we report a case of brain metastasis of ER-positive/HER2-negative primary breast cancer that initially responded to concomitant therapy of abemaciclib and letrozole, but required termination owing to drug-induced lung damage (DILD).

CASE PRESENTATION

Chief complaints

A postmenopausal woman in her 60s attended our hospital complaining of unsteadiness or dizziness.

History of present illness

Several months ago, the patient became aware of dizziness and the symptoms gradually worsened. She was not aware of nausea, paralysis, muscle weakness, or memory loss.

History of past illness

The woman underwent mastectomy and axillary lymph node dissection for breast cancer 11 years ago. The pathological diagnosis was mucinous carcinoma, histological grade 2, pT1c, n0(0/7), ER-positive, progesterone receptor-positive, and HER2-negative (score 0). For the 5 years after surgery, she received endocrine therapy and was no longer followed up after being recurrence-free for 10 years postoperatively.

Personal and family history

She had no particular personal and family medical history.

Physical examination


On physical examination, no notable abnormalities were observed.

Laboratory examinations

The laboratory examination results were unremarkable.

Imaging examinations

Head magnetic resonance imaging (MRI) indicated multiple brain metastases (Figure 1); no trunk lesions were observed on computed tomography (CT).



DOI: 10.12998/wjcc.v11.i35.8425 Copyright ©The Author(s) 2023.

Figure 1 Initial head magnetic resonance imaging. The patient was diagnosed with multiple brain metastases based on contrast-enhanced head magnetic resonance imaging when she visited our hospital for the staggering that she began experiencing in the 11th year postoperatively.

FINAL DIAGNOSIS

Late (more than 10 years after primary radical surgery) recurrence of breast cancer. Multiple brain metastases.

TREATMENT

After whole brain irradiation (40 Gy/20 Fr), exemestane treatment was initiated. Although the brain metastases showed partial response (PR), in the 12th year postoperatively, lymph node and adrenal metastases were detected by CT. Consequently, the treatment was changed to palbociclib plus letrozole. Thereafter, owing to deterioration of the pre-existing cerebellar metastasis, localized irradiation was performed. In the 13th year postoperatively, the brain metastases progressed (Figure 2A), so treatment was changed to abemaciclib plus letrozole as the third-line treatment. Three months later, MRI showed attenuation of the brain metastases and the contrast effect (Figure 2B), almost reaching a PR. However, DILD was noted on CT (Figure 3), which necessitated the termination of abemaciclib. No other grade 3 or higher hematological toxicity, diarrhea, or fatigue occurred.

OUTCOME AND FOLLOW-UP


The DILD improved after 1 mo of cessation. The patient continued treatments with TS-1 and fulvestrant but died in the 14th year postoperatively due to progression of the brain metastases.

DISCUSSION

We experienced a case in which abemaciclib was successful for brain metastasis of ER-positive/HER2-negative breast cancer but had to be discontinued due to DILD. Brain metastasis is reported to occur in 10%-15% of cases of advanced or recurrent breast cancer[1]. The mean survival after the appearance of brain metastasis varies depending on the subtype, ranging from several years for HER2-positive breast cancer to less than 6 mo for triple-negative (HER2, ER, and progesterone receptor all negative) breast cancer[5-7].


Breast cancer is recognized as a solid tumor that often responds well to pharmacotherapy, and advancements in translational research have significantly expanded the array of available drugs. However, conventional drugs are limited in their effectiveness for brain metastases of breast cancer due to the BBB and low cerebrospinal fluid penetration[8].

Some case reports and phase II trials have indicated a response rate of 5.2% to abemaciclib in brain metastases of ER-positive breast cancer and the overall outcomes have been less than satisfactory[9]. Capiivasertib (a protein kinase B inhibitor) and alpelisib (a phosphatidylinositol 3-kinase inhibitor) may have some potential for the treatment of brain metastasis of hormone receptor-positive breast cancer.



DOI: 10.12998/wjcc.v11.i35.8425 Copyright ©The Author(s) 2023.

Figure 2 Magnetic resonance imaging before and after abemaciclib administration. A: Contrast-enhanced head magnetic resonance imaging (MRI) before abemaciclib plus letrozole treatment; B: Contrast-enhanced head MRI after abemaciclib plus letrozole treatment. The brain metastases shrunk, and the contrast effect was attenuated after treatment, almost reaching a partial response.



DOI: 10.12998/wjcc.v11.i35.8425 Copyright ©The Author(s) 2023.

Figure 3 Computed tomography scan when diagnosing drug-induced lung disease. Computed tomography after abemaciclib plus letrozole treatment reveals a pale interstitial shadow on the right lung, which led to the diagnosis of drug-induced lung disease.

Trastuzumab-deruxtecan (T-DXd) is an antibody-drug conjugate that covalently binds trastuzumab, a humanized monoclonal antibody, with deruxtecan, a topoisomerase I inhibitor (a derivative of exatecan). T-DXd has shown promising results with a high response rate of 47.1% for brain metastases of HER2-positive breast cancer[10] owing to its unique mechanism of action. With HER2-low (HER2 score of 1 or 2 and fluorescence in situ hybridization-negative) recurrent metastatic breast cancer being added as an indication, T-DXd is expected to show effectiveness in brain metastases of breast cancer previously considered as ER-positive or triple-negative with low HER2 expression[11]. The first-line drug for ER-positive/HER2-negative metastatic/recurrent breast cancer is a CDK4/6 inhibitor, but if accompanied by brain metastases, T-Dxd may be a better first-line choice.

In global trials of abemaciclib (MONARCH 2, 3, and E)[12-14], DILD was reported in approximately 2%-3% of cases. Although DILD is not often fatal with appropriate monitoring and early intervention, in cases of grade 2 or higher severity, treatment must often be terminated without the possibility of it being resumed. Underlying lung diseases such as interstitial pneumonia can be risk factors for DILD, but the exact mechanism of onset is not fully understood, and preventive measures have not yet been established. CDK4/6 inhibitors, abemaciclib, and palbociclib can be prescribed

under Japanese insurance; however, palbociclib has a high incidence of hematological toxicity. In particular, neutropenia was reported in 78% (66% grade 3) of cases in a phase III[3] study. Abemaciclib also has hematological toxicity[12-14], however can be clinically characterized by non-hematological toxicity symptoms, such as diarrhea and fatigue.

As this is a case report, our findings have not been validated, however, they may provide an opportunity to consider the factors involved leading to treatment termination due to adverse events. This is critical as there are no drugs that have shown significant efficacy on brain metastases of breast cancer.

CONCLUSION

We present the case of a patient with brain metastases from primary breast cancer where abemaciclib was terminated owing to DILD. While we anticipate the development of drugs that are effective for brain metastases, exploring strategies to minimize treatment terminations due to toxicities remains an important approach.

ACKNOWLEDGEMENTS

This case was presented at the 30th Annual Meeting of the Japanese Breast Cancer Society (June 30, 2022).

FOOTNOTES

Author contributions: Yamashiro H and Morii N contributed to manuscript writing and editing; all authors have read and approved the final manuscript.

Informed consent statement: Although the informed written consent cannot be obtained because the patient has already died, I can state clearly that this case report does not contain information that could identify the individual patient.

Conflict-of-interest statement: Hiroyasu Yamashiro received honoraria from Chugai, Novartis, Takeda, Eisai, Daiichi-Sankyo and AstraZeneca, Pfizer, Eli Lilly and Kyowa-Kirin outside this work. Nao Morii received honoraria from Eli Lilly outside this work.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Japan

ORCID number: Hiroyasu Yamashiro 0000-0003-1778-6735.

S-Editor: Qu XL

L-Editor: A

P-Editor: Qu XL

REFERENCES

- 1 Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. *Clin Cancer Res* 2013; **19**: 6404-6418 [PMID: 24298071 DOI: 10.1158/1078-0432.CCR-13-0790]
- 2 Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014; **32**: 2100-2108 [PMID: 24799487 DOI: 10.1200/JCO.2013.54.0955]
- 3 Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. *N Engl J Med* 2016; **375**: 1925-1936 [PMID: 27959613 DOI: 10.1056/NEJMoa1607303]
- 4 Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. *Cancer Discov* 2016; **6**: 740-753 [PMID: 27217383 DOI: 10.1158/2159-8290.CD-16-0095]
- 5 Matsuo S, Watanabe J, Mitsuya K, Hayashi N, Nakasu Y, Hayashi M. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. *Breast Cancer Res Treat* 2017; **162**: 169-179 [PMID: 28084583 DOI: 10.1007/s10545-017-0000-0]

10.1007/s10549-017-4107-x]

- 6 **Hurvitz SA**, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. *Clin Cancer Res* 2019; **25**: 2433-2441 [PMID: 30593513 DOI: 10.1158/1078-0432.CCR-18-2366]
- 7 **Rostami R**, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. *J Neurooncol* 2016; **127**: 407-414 [PMID: 26909695 DOI: 10.1007/s11060-016-2075-3]
- 8 **Sun A**, Wang J. Choroid Plexus and Drug Removal Mechanisms. *AAPS J* 2021; **23**: 61 [PMID: 33942198 DOI: 10.1208/s12248-021-00587-9]
- 9 **Tolaney SM**, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. *Clin Cancer Res* 2020; **26**: 5310-5319 [PMID: 32694159 DOI: 10.1158/1078-0432.CCR-20-1764]
- 10 **Jerusalem G**, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, Krop IE, González Farré X, You B, Saura C, Kim SB, Osborne CR, Murthy RK, Gianni L, Takano T, Liu Y, Cathcart J, Lee C, Perrin C. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. *Cancer Discov* 2022; **12**: 2754-2762 [PMID: 36255231 DOI: 10.1158/2159-8290.CD-22-0837]
- 11 **Kabraji S**, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. *Clin Cancer Res* 2023; **29**: 174-182 [PMID: 36074155 DOI: 10.1158/1078-0432.CCR-22-1138]
- 12 **Sledge GW Jr**, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol* 2017; **35**: 2875-2884 [PMID: 28580882 DOI: 10.1200/JCO.2017.73.7585]
- 13 **Goetz MP**, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin Oncol* 2017; **35**: 3638-3646 [PMID: 28968163 DOI: 10.1200/JCO.2017.75.6155]
- 14 **Johnston SRD**, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol* 2020; **38**: 3987-3998 [PMID: 32954927 DOI: 10.1200/JCO.20.02514]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

